Our Company Overview

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for TH104 and TH023, a new approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

Press Releases

Latest Financial Results

Q1 2024 – QUERTER ENDED MAR 31, 2024

XBRL

Sign Up For Latest
News and Press Releases

Receive updates straight into your inbox